BMRN Biomarin Pharmaceutical Inc
Price (delayed)
$68.25
Market cap
$13.01B
P/E Ratio
40.15
Dividend/share
N/A
EPS
$1.7
Enterprise value
$12.93B
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for serious and life-threatening rare and ultra-rare genetic diseases. The Company's portfolio consists of six commercialized products and
Highlights
Biomarin Pharmaceutical's EPS has surged by 121% YoY and by 26% QoQ
The net income has surged by 119% year-on-year and by 26% since the previous quarter
Key stats
What are the main financial stats of BMRN
Market
Valuations
Earnings
Shares outstanding
190.58M
Market cap
$13.01B
Enterprise value
$12.93B
Price to earnings (P/E)
40.15
Price to book (P/B)
2.4
Price to sales (P/S)
4.72
EV/EBIT
31.71
EV/EBITDA
25.48
EV/Sales
4.7
Revenue
$2.75B
Gross profit
$2.17B
Operating income
$337.03M
Net income
$322.29M
EBIT
$407.64M
EBITDA
$507.32M
Free cash flow
$329.89M
Per share
Balance sheet
Liquidity
EPS
$1.7
EPS diluted
$1.66
Free cash flow per share
$1.73
Book value per share
$28.43
Revenue per share
$14.46
TBVPS
$33.58
Total assets
$6.85B
Total liabilities
$1.44B
Debt
$594.63M
Equity
$5.41B
Working capital
$2.34B
Debt to equity
0.11
Current ratio
4.27
Quick ratio
2.39
Net debt/EBITDA
-0.16
Margins
Efficiency
Dividend
EBITDA margin
18.4%
Gross margin
78.9%
Net margin
11.7%
Operating margin
12.2%
Return on assets
4.7%
Return on equity
6.2%
Return on invested capital
7.3%
Return on capital employed
6.6%
Return on sales
14.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BMRN stock price
How has the Biomarin Pharmaceutical stock price performed over time
Intraday
-0.7%
1 week
5.24%
1 month
9.15%
1 year
-22.92%
YTD
3.83%
QTD
3.83%
Financial performance
How have Biomarin Pharmaceutical's revenue and profit performed over time
Revenue
$2.75B
Gross profit
$2.17B
Operating income
$337.03M
Net income
$322.29M
Gross margin
78.9%
Net margin
11.7%
The operating income has surged by 152% year-on-year and by 33% since the previous quarter
The net income has surged by 119% year-on-year and by 26% since the previous quarter
Biomarin Pharmaceutical's operating margin has soared by 110% YoY and by 24% from the previous quarter
The net margin has soared by 83% year-on-year and by 18% since the previous quarter
Growth
What is Biomarin Pharmaceutical's growth rate over time
Valuation
What is Biomarin Pharmaceutical stock price valuation
P/E
40.15
P/B
2.4
P/S
4.72
EV/EBIT
31.71
EV/EBITDA
25.48
EV/Sales
4.7
Biomarin Pharmaceutical's EPS has surged by 121% YoY and by 26% QoQ
BMRN's P/E is 79% below its 5-year quarterly average of 193.4 and 45% below its last 4 quarters average of 72.7
The stock's price to book (P/B) is 35% less than its 5-year quarterly average of 3.7 and 23% less than its last 4 quarters average of 3.1
The equity has grown by 11% YoY and by 2.4% from the previous quarter
BMRN's price to sales (P/S) is 39% less than its 5-year quarterly average of 7.8 and 25% less than its last 4 quarters average of 6.3
The revenue has grown by 19% YoY and by 6% from the previous quarter
Efficiency
How efficient is Biomarin Pharmaceutical business performance
Biomarin Pharmaceutical's ROIC has soared by 152% YoY and by 28% from the previous quarter
Biomarin Pharmaceutical's return on sales has surged by 106% YoY and by 21% QoQ
BMRN's return on assets has surged by 104% year-on-year and by 27% since the previous quarter
The ROE has soared by 100% YoY and by 22% from the previous quarter
Dividends
What is BMRN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BMRN.
Financial health
How did Biomarin Pharmaceutical financials performed over time
The company's current ratio has surged by 68% YoY and by 40% QoQ
BMRN's quick ratio has surged by 64% year-on-year and by 34% since the previous quarter
The debt is 89% smaller than the equity
BMRN's debt to equity has dropped by 50% year-on-year and by 48% since the previous quarter
The debt is down by 45% since the previous quarter and by 45% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.